BioNTech Shares Plummet 8% After mRNA Cancer Vaccine Trial Discontinuation
BioNTech's shares plummeted by approximately 8% on Friday after the company announced it was discontinuing a Phase 2 study for its mRNA cancer vaccine, autogene cevumeran. The decision came after an independent safety monitoring committee determined that continuing with the trial would be futile due to disparities in survival data across treatment arms.
The trial, which was testing autogene cevumeran as an adjunctive therapy for high-risk Stage II or Stage III colorectal cancer patients who had undergone surgical intervention, had previously reached its futility threshold in October 2025. However, at that time, the monitoring committee determined the available data lacked sufficient maturity to support definitive conclusions regarding treatment effectiveness.
This marks the second setback for autogene cevumeran this year, after a bladder cancer study was discontinued in March. The news comes as a stark contrast to recent positive momentum in the mRNA space, triggered by Moderna and Merck's successful Phase 3 melanoma vaccine results.
BioNTech maintains a robust balance sheet with €16.6 billion in liquid assets, but the company's Chief Medical Officer, Prof. Özlem Türeci, characterized the outcomes as 'disappointing'. She emphasized that the scientific knowledge gained regarding immune-suppressive tumor resistance mechanisms would inform the development of future mRNA-based cancer treatments.
One clinical program remains active, BioNTech's Phase 2 pancreatic cancer trial, which evaluates autogene cevumeran combined with checkpoint inhibition therapy and chemotherapy. The company also anticipates an interim data readout from its BNT113 study targeting head and neck cancer.